The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Autor: Jong Hyun Choi, M.D., Juwhan Choi, M.D., Sang Mi Chung, M.D., Jee Youn Oh, M.D., Ph.D., Young Seok Lee, M.D., Ph.D., Kyung Hoon Min, M.D., Ph.D., Gyu Young Hur, M.D., Ph.D., Jae Jeong Shim, M.D., Ph.D., Kyung Ho Kang, M.D., Ph.D., Hyun Kyung Lee, M.D., Ph.D., Sung Yong Lee, M.D., Ph.D.
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Tuberculosis and Respiratory Diseases, Vol 82, Iss 3, Pp 211-216 (2019)
Druh dokumentu: article
ISSN: 1738-3536
2005-6184
DOI: 10.4046/trd.2018.0019&code=0003TRD&vmode=FULL
Popis: Background Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.
Databáze: Directory of Open Access Journals
Externí odkaz: